Arno Therapeutics Inc.

Arno Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapeutics. Its primary mission is to address significant unmet medical needs by advancing targeted cancer treatments and novel drug candidates. The company’s pipeline features several small molecule drugs, with lead candidates including Onapristone—for endometrial, prostate, and breast cancers—AR-42 for hematological malignancies and solid tumors, and AR-12 for both solid tumors, blood cancers, and anti-microbial applications. Onapristone is notable as a type 1 anti-progestin hormone blocker with demonstrated anti-tumor activity, particularly in breast cancer patients, while AR-42 acts as a spectrum deacetylase inhibitor targeting both histone and non-histone proteins. AR-12, an oral therapy, is being explored for various cancer types and infectious diseases. Founded in 2000 and operating with a lean team, Arno Therapeutics contributes to the biotechnology sector by focusing on early-stage, high-need therapeutic areas, striving to develop effective treatments for life-threatening conditions where current options are limited.